167 related articles for article (PubMed ID: 15784340)
1. The role of physicochemical properties of entacapone and tolcapone on their efficacy during local intrastriatal administration.
Forsberg MM; Huotari M; Savolainen J; Männistö PT
Eur J Pharm Sci; 2005 Apr; 24(5):503-11. PubMed ID: 15784340
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and pharmacodynamics of entacapone and tolcapone after acute and repeated administration: a comparative study in the rat.
Forsberg M; Lehtonen M; Heikkinen M; Savolainen J; Järvinen T; Männistö PT
J Pharmacol Exp Ther; 2003 Feb; 304(2):498-506. PubMed ID: 12538800
[TBL] [Abstract][Full Text] [Related]
3. Effects of peripheral and central catechol-O-methyltransferase inhibition on striatal extracellular levels of dopamine: a microdialysis study in freely moving rats.
Napolitano A; Bellini G; Borroni E; Zürcher G; Bonuccelli U
Parkinsonism Relat Disord; 2003 Jan; 9(3):145-50. PubMed ID: 12573869
[TBL] [Abstract][Full Text] [Related]
4. Effect of intracerebral 6-nitronoradrenaline, an endogenous catechol-O-methyltransferase (COMT) inhibitor, on striatal dopamine metabolism in anaesthetised rats.
Huotari M; Passlin M; Nordberg HL; Forsberg M; Kotisaari S; Tuomisto L; Shintani F; Tanaka KF; Reenilä I; Laitinen K; Männistö PT
J Neurosci Methods; 2001 Aug; 109(1):47-52. PubMed ID: 11489299
[TBL] [Abstract][Full Text] [Related]
5. Modulation of rat brain endogenous dopamine metabolism by new inhibitors of catechol O-methyltransferase.
Törnwall M; Tuomainen P; Männistö PT
Eur J Pharmacol; 1993 Aug; 239(1-3):39-45. PubMed ID: 8223912
[TBL] [Abstract][Full Text] [Related]
6. Synergistic inhibition of lung cancer cell lines by (-)-epigallocatechin-3-gallate in combination with clinically used nitrocatechol inhibitors of catechol-O-methyltransferase.
Forester SC; Lambert JD
Carcinogenesis; 2014 Feb; 35(2):365-72. PubMed ID: 24148818
[TBL] [Abstract][Full Text] [Related]
7. The central catechol-O-methyltransferase inhibitor tolcapone increases striatal hydroxyl radical production in L-DOPA/carbidopa treated rats.
Gerlach M; Xiao AY; Kuhn W; Lehnfeld R; Waldmeier P; Sontag KH; Riederer P
J Neural Transm (Vienna); 2001; 108(2):189-204. PubMed ID: 11314772
[TBL] [Abstract][Full Text] [Related]
8. [Microdialysis study of tolcapone effect during blockage of neuronal dopamine reuptake caused by GBR-12909].
Budygin EA; Gaĭnetdinov RR; Raevskiĭ KS; Li IH; Mannisto PT
Eksp Klin Farmakol; 1997; 60(5):8-10. PubMed ID: 9483396
[TBL] [Abstract][Full Text] [Related]
9. Effects of CGP 28014 on the in vivo release and metabolism of dopamine in the rat striatum assessed by brain microdialysis.
Steulet AF; Stöcklin K; Wicki P; Waldmeier P
Neurochem Res; 1993 Nov; 18(11):1131-6. PubMed ID: 8255364
[TBL] [Abstract][Full Text] [Related]
10. Different modes of action of catecholamine-O-methyltransferase inhibitors entacapone and tolcapone on adenylyl cyclase activity in vitro.
Gerlach M; Ukai W; Ozawa H; Riederer P
J Neural Transm (Vienna); 2002 May; 109(5-6):789-95. PubMed ID: 12111468
[TBL] [Abstract][Full Text] [Related]
11. Problems with the present inhibitors and a relevance of new and improved COMT inhibitors in Parkinson's disease.
Kaakkola S
Int Rev Neurobiol; 2010; 95():207-25. PubMed ID: 21095464
[TBL] [Abstract][Full Text] [Related]
12. Glucuronidation of entacapone, nitecapone, tolcapone, and some other nitrocatechols by rat liver microsomes.
Lautala P; Kivimaa M; Salomies H; Elovaara E; Taskinen J
Pharm Res; 1997 Oct; 14(10):1444-8. PubMed ID: 9358559
[TBL] [Abstract][Full Text] [Related]
13. General properties and clinical possibilities of new selective inhibitors of catechol O-methyltransferase.
Kaakkola S; Gordin A; Männistö PT
Gen Pharmacol; 1994 Sep; 25(5):813-24. PubMed ID: 7835624
[TBL] [Abstract][Full Text] [Related]
14. Effects of COMT inhibitors on striatal dopamine metabolism: a microdialysis study.
Kaakkola S; Wurtman RJ
Brain Res; 1992 Aug; 587(2):241-9. PubMed ID: 1381981
[TBL] [Abstract][Full Text] [Related]
15. No change of brain extracellular catecholamine levels after acute catechol-O-methyltransferase inhibition: a microdialysis study in anaesthetized rats.
Li YH; Wirth T; Huotari M; Laitinen K; MacDonald E; Männistö PT
Eur J Pharmacol; 1998 Sep; 356(2-3):127-37. PubMed ID: 9774242
[TBL] [Abstract][Full Text] [Related]
16. Microdialysis studies on the action of tolcapone on pharmacologically-elevated extracellular dopamine levels in conscious rats.
Huotari M; Gainetdinov R; Männistö PT
Pharmacol Toxicol; 1999 Nov; 85(5):233-8. PubMed ID: 10608486
[TBL] [Abstract][Full Text] [Related]
17. [Effect of subchronic administration of tolcapone on release of striatum dopamine and its metabolites induced by L-DOPA and carbidopa].
Budygin EA; Gaĭnetdinov RR; Raevskiĭ KS; Mannisto PT
Biull Eksp Biol Med; 1998 Feb; 125(2):168-71. PubMed ID: 9559129
[No Abstract] [Full Text] [Related]
18. Different in vivo properties of three new inhibitors of catechol O-methyltransferase in the rat.
Männistö PT; Tuomainen P; Tuominen RK
Br J Pharmacol; 1992 Mar; 105(3):569-74. PubMed ID: 1628144
[TBL] [Abstract][Full Text] [Related]
19. Effects of tolcapone upon soluble and membrane-bound brain and liver catechol-O-methyltransferase.
Vieira-Coelho MA; Soares-da-Silva P
Brain Res; 1999 Mar; 821(1):69-78. PubMed ID: 10064789
[TBL] [Abstract][Full Text] [Related]
20. Differences in toxicity of the catechol-O-methyl transferase inhibitors, tolcapone and entacapone to cultured human neuroblastoma cells.
Korlipara LV; Cooper JM; Schapira AH
Neuropharmacology; 2004 Mar; 46(4):562-9. PubMed ID: 14975680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
